Literature DB >> 2757906

Interaction between vigabatrin and phenytoin.

E M Rimmer1, A Richens.   

Abstract

1. The study was designed to determine the mechanism by which vigabatrin causes a fall in plasma phenytoin concentrations when added to the drug therapy of eight epileptic patients. 2. Total plasma phenytoin concentration was measured before and at intervals during 5 weeks' treatment with vigabatrin. 3. Plasma protein binding of phenytoin, the urinary ratio of phenytoin to 5-(p-hydroxyphenyl)-5-phenylhydantoin, and antipyrine clearance were measured before and at the end of treatment period. 4. Mean plasma phenytoin concentration fell significantly by 23% during the fifth week. 5. No change was found in any of the other measures. 6. Although an interaction between phenytoin and vigabatrin has been confirmed, the mechanism has not been elucidated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757906      PMCID: PMC1379676          DOI: 10.1111/j.1365-2125.1989.tb03458.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Assessment of antipyrine kinetics by measurement in saliva.

Authors:  H S Fraser; J C Mucklow; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

3.  Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up.

Authors:  T R Browne; R H Mattson; J K Penry; D B Smith; D M Treiman; B J Wilder; E Ben-Menachem; M J Napoliello; K M Sherry; G K Szabo
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910

4.  The renal handling of diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin.

Authors:  F Bochner; W D Hooper; J M Sutherland; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

5.  Assay of the major (4-hydroxylated) metabolites of diphenylhydantoin in human urine.

Authors:  B Karlén; M Garle; A Rane; M Gutova; B Lindborg
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

6.  A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

Authors:  E Perucca; A Hedges; K A Makki; M Ruprah; J F Wilson; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

7.  Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy.

Authors:  E M Rimmer; A Richens
Journal:  Lancet       Date:  1984-01-28       Impact factor: 79.321

8.  Should we routinely measure free plasma phenytoin concentration?

Authors:  E M Rimmer; D C Buss; P A Routledge; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

9.  Kinetics of low-dose intravenous antipyrine: use of liquid chromatography.

Authors:  D J Greenblatt; D R Abernethy; M Divoll
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1983-02

10.  Decreased plasma protein binding of phenytoin in patients on valproic acid.

Authors:  R Dahlqvist; O Borgå; A Rane; Z Walsh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

View more
  21 in total

Review 1.  Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.

Authors:  K Wilbur; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 2.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 4.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 5.  Pharmacokinetic interactions of the new antiepileptic drugs.

Authors:  B Rambeck; U Specht; P Wolf
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 6.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

Review 7.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 8.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 9.  Vigabatrin. Clinical pharmacokinetics.

Authors:  E Rey; G Pons; G Olive
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

10.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.